Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Brand name: Recombinate

Recombinate is a medicine containing the active ingredient(s) octocog alfa. On this page you will find out more about Recombinate, including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.

Active ingredient in this medicine: octocog alfa

Pack size information

Please select the pack size from the options directly below to view information on the medicine.

Information for medicine and pack size:
Recombinate (1 x 250 units vial, 1 x 10 mL inert diluent vial), 1 pack

Consumer Medicine Information leaflet:

This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.

Read leaflet

What this medicine is for

Recombinate is indicated for use in haemophilia A (classical haemophilia) for the prevention and control of haemorrhagic episodes. Patients with haemophilia A may be treated with Recombinate as perioperative management. Recombinate is not indicated in von Willebrand's disease.

Table of characteristics
Table of characteristics
Active ingredient
Medicine schedule
1 x 250IU: Not scheduled. Not considered by committee
1 x transfer needle and 1 x filter needle: Not scheduled. Not considered by committee
10mL diluent: Not scheduled. Not considered by committee
Part 1
Part 1
Visual appearance Off-white to faint yellow powder or friable solid.
Dosage Form Injection, powder for
Route of administration Intravenous
Part 2
Part 2
Visual appearance Clear colourless solution.
Dosage Form Diluent, not applicable
Route of administration Intravenous

There is one type of pack available.

Pack type 1
Pack type 1
Type Multiple containers
Storage temperature Store at 2 to 8 degrees Celsius
Storage conditions Do not Freeze
Life time 3 Years
We were unable to verify that this medicine is available on the PBS (Pharmaceutical Benefits Scheme). Please consult your pharmacist if you need further information

The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.

Go to PBS site

Is this medication banned in sport?

Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.

Go to ASADA site

The information displayed on this page is authored by Healthdirect Australia, or obtained from trusted sources.

Need more information?

These trusted information partners have more on this topic.

Found 70 results

Recombinate Powder for injection -

Recombinate Powder for injection - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

Rapilysin | myVMC

Rapilysin is a treatment for acute heart attack, administered within six hours of onset. It contains reteplase, a recombinant plasminogen activator.

Read more on myVMC – Virtual Medical Centre website

NovoSeven | myVMC

Novoseven is a treatment for blood coagulation disorders including haemophilia. It contains Eptacog alfa (activated- bhk) a recombinant coagulation factor.

Read more on myVMC – Virtual Medical Centre website

Refludan | myVMC

Refludan is used to treat acute heparin induced thrombocytopaenia (HIT) type II. It contains lepirudin is a recombinant hirudin with anticoagulant effects.

Read more on myVMC – Virtual Medical Centre website

Metalyse | myVMC

Metalyse is used to treat acute heart attack. It contains tenecteplase, an intravenously administered recombinant plasminogen activator.

Read more on myVMC – Virtual Medical Centre website

Erbitux | myVMC

Erbitux is an anti-cancer medicine used to treat colorectal cancer. It contains cetuximab, a recombinant chimeric monoclonal antibody.

Read more on myVMC – Virtual Medical Centre website

Haemophilia A | myVMC

Haemophilia A involves a genetic defect causing abnormality of blood clotting

Read more on myVMC – Virtual Medical Centre website

Xigris | myVMC

Xigris is used to reduce the risk of death in people with sepsis. It contains drotrecogin alfa, a synthetic human activated protein C.

Read more on myVMC – Virtual Medical Centre website

BeneFIX (nonacog alfa (rch)) information | myVMC

BeneFIX (nonacog alfa (rch)) is used for the control and treatment of bleeding and the prevention of bleeding in patients with haemophilia B.

Read more on myVMC – Virtual Medical Centre website

Avelox | myVMC

Avelox is used to treat respiratory infections. It contains moxifloxacin, a synthetic, broad spectrum quinolone antibiotic with bactericidal action.

Read more on myVMC – Virtual Medical Centre website

Check your symptoms Find a health service

Healthdirect 24hr 7 days a week hotline

24 hour health advice and information you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Government of South Australia, health department logo Tasmanian government logo Government of Western Australia, health department logo